{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:31:25Z","timestamp":1793745085118,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.041","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:49:37Z","timestamp":1787464177000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduced-Dose Post-Transplant Cyclophosphamide (PTCy 40-40) in Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7642-0461","authenticated-orcid":false,"given":"Lauren","family":"Scarpetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4601-1018","authenticated-orcid":false,"given":"Jeremy","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-0143","authenticated-orcid":false,"given":"Jooho","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"McAfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-6961","authenticated-orcid":false,"given":"Richard","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-2063","authenticated-orcid":false,"given":"Gregory","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1384-5742","authenticated-orcid":false,"given":"Thomas","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-3880","authenticated-orcid":false,"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-1643","authenticated-orcid":false,"given":"Gabriela","family":"Sanchez-Petitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2849-2989","authenticated-orcid":false,"given":"Hannah","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2026.08.041_bib0001","first-page":"174.e112","article-title":"Donor type does not impact late graft failure following reduced-intensity allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"31","author":"Hickey","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.041_bib0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2026.08.041_bib0003","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1182\/bloodadvances.2021004846","article-title":"Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era","volume":"5","author":"Yeh","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.041_bib0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.041_bib0005","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jtct.2024.03.018","article-title":"Graft failure incidence, risk factors, and outcomes in patients undergoing non-myeloablative allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide","volume":"30","author":"Mata","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.041_bib0006","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood-2019-121659","article-title":"Graft failure after haploidentical hematopoietic stem cell transplantation","volume":"134","author":"Hickey","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.08.041_bib0007","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/blood-2024-210332","article-title":"Efficacy and safety of reduced-doses of post-transplant cyclophosphamide in matched peripheral blood stem cell transplantation, a multicenter study","volume":"144","author":"Lopez-Garcia","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.041_bib0008","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.jtct.2026.08.041_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142567","article-title":"Reduced dose of post-transplant cyclophosphamide with tacrolimus for the prevention of graft-versus-host disease in HLA-matched donor peripheral blood stem cell transplants: a prospective pilot study","volume":"16","author":"Ju\u00e1rez","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.041_bib0010","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41409-023-02085-2","article-title":"Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.08.041_bib0011","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2023-189430","article-title":"Phase I\/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-identical peripheral blood hematopoietic stem cell transplantation","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.041_bib0012","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.041_bib0013","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Zu","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.041_bib0014","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.exphem.2015.07.006","article-title":"HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome","volume":"43","author":"Nakamae","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2026.08.041_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221112098","article-title":"A prospective study of an HLA-haploidentical peripheral blood stem cell transplantation regimen based on modification of the dose of posttransplant cyclophosphamide for poor prognosis or refractory hematological malignancies","volume":"31","author":"Nakamae","year":"2022","journal-title":"Cell Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.041_bib0016","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41409-021-01358-y","article-title":"Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation","volume":"56","author":"Sun","year":"2021","journal-title":"Bone Marrow Transplantation"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.041_bib0017","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/s41409-024-02405-0","article-title":"Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation","volume":"59","author":"Fuji","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.041_bib0018","first-page":"473.e471","article-title":"Successful outcome in patients with myelofibrosis undergoing allogeneic donor hematopoietic cell transplantation using reduced doses of post-transplantation cyclophosphamide: challenges and review of the literature","volume":"29","author":"Garc\u00eda-Cadenas","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.08.041_bib0019","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1182\/blood-2018-99-112436","article-title":"Reduced dose of post-transplant cyclophosphamide for HLA haploidentical peripheral blood stem cell transplantation","volume":"132","author":"Morishige","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.041_bib0020","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-019-03673-3","article-title":"Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study","volume":"98","author":"Soltermann","year":"2019","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.041_bib0021","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jha2.962","article-title":"Combination of reduced post-transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft-versus-host disease in human leukocyte antigen-haploidentical peripheral blood stem-cell transplantation","volume":"5","author":"Terao","year":"2024","journal-title":"EJHaem"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.041_bib0022","doi-asserted-by":"crossref","first-page":"298.e1","DOI":"10.1016\/j.jtct.2025.10.020","article-title":"Modifying post-transplant cyclophosphamide platform to improve safety in HLA-matched allogeneic HCT: a reduced dose plus adjunctive strategies","volume":"32","author":"Pinto","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.041_bib0023","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/j.jtct.2024.02.010","article-title":"Reducing Ptcy dose in patients receiving CAST for GvHD prevention results in accelerated engraftment at the cost of higher incidence of GvHD","volume":"30","author":"Londono","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.041_bib0024","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3109\/10428194.2014.930849","article-title":"Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients","volume":"56","author":"Ferr\u00e0","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.041_bib0025","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.041_bib0026","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.041_bib0027","unstructured":"KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. 2. Official Journal Of The International Society of Nephrology; 2012.https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2012-AKI-Guideline-English.pdf. Accessed March 3, 2025."},{"issue":"3","key":"10.1016\/j.jtct.2026.08.041_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.041_bib0029","first-page":"667.e1","article-title":"Incidence of and risk factors for delayed engraftment after post-transplant cyclophosphamide","volume":"32","author":"Scarpetti","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.041_bib0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtct.2025.09.009","article-title":"The heart of the matter: cardiac toxicity in allogenic stem cell transplant with post-transplant cyclophosphamide","volume":"32","author":"Gradone","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2026.08.041_bib0031","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/bloodadvances.2025015964","article-title":"Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703","volume":"9","author":"Abedin","year":"2025","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.jtct.2026.08.041_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17193128","article-title":"Safety of post-transplant cyclophosphamide-based prophylaxis in AML patients with pre-existing cardiac morbidity undergoing allogeneic hematopoietic cell transplantation","volume":"17","author":"Torrent-Rodr\u00edguez","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.jtct.2026.08.041_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17244029","article-title":"Complications of haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide-a prospective study on behalf of the EBMT transplant complications working party","volume":"17","author":"Tomaszewska","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.041_bib0034","first-page":"2227","article-title":"Risk of post-transplant cyclophosphamide-related cardiotoxicity in allogeneic stem cell transplantation","volume":"42","author":"Hadjali","year":"2026","journal-title":"Can J Cardiol"},{"issue":"25","key":"10.1016\/j.jtct.2026.08.041_bib0035","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO-25-00856","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","volume":"43","author":"Malki","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.041_bib0036","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtct.2023.12.021","article-title":"Interim results of a phase I\/II trial of intermediate-dose post-transplantation cyclophosphamide after reduced intensity conditioned HLA-mismatched bone marrow transplantation for older or unfit patients","volume":"30","author":"McCurdy","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.041_bib0037","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose post-transplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","volume":"9","author":"Hyder","year":"2025","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:37:19Z","timestamp":1789875439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S2666636726006834"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.041","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-Dose Post-Transplant Cyclophosphamide (PTCy 40-40) in Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}